Efficacy of Fexuprazan for Prevention or Control of Gastritis Symptoms in Patients on Treatment With Systemic Steroids

NCT ID: NCT05946135

Last Updated: 2026-01-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 42 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-11-07
• Study Completion Date: 2025-09-08

Brief Summary

• This clinical trial is conducted as a double-blind, randomized, and active drug control clinical trial. If the screening results determine that the selection/exclusion criteria are met, the clinical trial drugs are randomly assigned at a 1:1 ratio of the Pexuprazan 40 mg and the Lansoprazole 15 mg dose group and taken for 4 weeks.
• Gastritis symptoms are evaluated four weeks after baseline (Visit1) and clinical drug administration (Visit2), and if it is determined that gastritis is necessary according to the medical team's judgment due to gastrointestinal symptoms during the study participation period, endoscopy is performed to check whether gastritis occurs.

Conditions

Patients on Treatment With Systemic Steroids

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Control

lansoprazole + placebo for Fexuprazan Hydrochloride

Group Type: ACTIVE_COMPARATOR

Lansoprazole

Intervention Type: DRUG

taking lansoprazole + placebo for Fexuprazan Hydrochloride for 4 weeks

Intervention

placebo for lansoprazole + Fexuprazan Hydrochloride

Group Type: EXPERIMENTAL

Fexuprazan Hydrochloride

Intervention Type: DRUG

taking placebo for lansoprazole + Fexuprazan Hydrochloride for 4 weeks

Interventions

Lansoprazole

taking lansoprazole + placebo for Fexuprazan Hydrochloride for 4 weeks

Intervention Type: DRUG

Fexuprazan Hydrochloride

taking placebo for lansoprazole + Fexuprazan Hydrochloride for 4 weeks

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. A person who voluntarily signed a consent form

2. Adult men and women over 20 years of age

3. Patients who require systemic steroid treatment of at least 4 weeks of moderate dose (20 mg/day or more based on prednisolone) due to respiratory diseases during screening

• Patients who are already on steroids can also participate (If there is a gastric protective agent in use, patients should agree to replace it with clinical trial drug)

4. Patients who satisfy both of the following in relation to the evaluation index of gastritis symptoms during screening

• Gastritis symptom frequency indicator: 5 points or less

• Gastritis symptom intensity indicator: 5 points or less

5. A person who has at least one of the following risk factors for gastric ulcer during screening

① Long-term use of NSAIDs for longer than 12 weeks (NSAIDs should be maintained continuously during the clinical trial.)

② A person who has a history of peptic ulcer in the past

③ 50 years of age or older

④ In combination with low-dose aspirin (aspirin 325 mg/day or less) (Low-dose aspirin should be maintained continuously during the clinical trial.)

6. A person who understand and follow the guidance of the research manager according to the research plan, and who can participate whole period of clinical trial

Exclusion Criteria

1. A person who has a hypersensitivity reaction to the components of this clinical trial drug or benzimidazole-based drug or has a history of clinically significant hypersensitivity reaction

2. A person who has undergone surgery that may affect gastric acid secretion, such as upper gastrointestinal resection, gastric acid secretion inhibition surgery, and gastric mucosal resection

3. Those who have a history of gastrointestinal malignancies within 5 years of screening (excluding after endoscopic resection of gastric carcinoma or early gastric cancer)

4. Patients with Barrett's esophagus (over 3 cm), gastroesophageal varices, esophageal stenosis, ulcer stenosis, active peptic ulcers, and acute gastrointestinal bleeding

5. Patients with inflammatory bowel disease (Crohn's disease, ulcerative colitis, etc.), irritable bowel syndrome (IBS), primary esophageal motility disorder, and pancreatitis

6. Patients with eosinophilic esophagitis (if the esophageal biopsy determines that it is not eosinophilic esophagitis, they can participate)

7. Those who have a history of gastric acid secretion disorders such as Zolinger-Elison syndrome

8. A person who is currently confirmed positive for Helicobacter pyrroly infection

9. Persons taking medications contraindicated to clinical trial drug (e.g., atazanavir, nelfinavir, or rilpivirine-containing agents)

10. Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose absorption disorder

11. Patients with severe renal and liver disorders according to the physician's judgment

12. A person who disagrees with the appropriate use of contraception by himself/herself or his/her partner during the clinical trial period

13. Pregnant women or breast feeding women

14. Any person who has any clinical findings that are deemed medically inappropriate for this trial under the judgment of the research manager

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Yonsei University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ji Ye Jung

Role: PRINCIPAL_INVESTIGATOR

Severance Hospital, Division of Pulmonary and Critical Care Medicine

Locations

Severance Hospital

Seoul, , South Korea

Countries

South Korea

Other Identifiers

4-2023-0598

Identifier Type: -

Identifier Source: org_study_id